TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through the FAK/AKT/Mtor-gpx4 cascade
Chemotherapy remains a pivotal strategy in the treatment of pancreatic ductal adenocarcinoma (PDAC). Nonetheless, the emergence of drug resistance has limited the clinical efficacy of chemotherapeutic agents, especially gemcitabine. Here, we identified tetraspanin-15 (TSPAN15), a member of the tetra...
Saved in:
| Main Authors: | Peng Nan, Xiao Wang, Anan Li, Yumei Ge, Zongting Gu, Yingying Wang, Ran Tao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Redox Biology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231725002344 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01) -
An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer
by: REN Jiaqiang, WU Shuai, SU Tong, LI Jie, HAN Liang, WU Zheng
Published: (2024-12-01) -
ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis
by: Xiaohong Liu, et al.
Published: (2025-08-01) -
Pancreatic ductal adenocarcinoma in a patient with pancreas divisum and gastrointestinal duplication cyst: a case report
by: Naoto Takahashi, et al.
Published: (2021-08-01) -
Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy
by: M. Sugimori, et al.
Published: (2025-09-01)